Transatlantique Private Wealth LLC Decreases Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Transatlantique Private Wealth LLC trimmed its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 29.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,796 shares of the medical equipment provider’s stock after selling 2,048 shares during the period. Transatlantique Private Wealth LLC’s holdings in Hologic were worth $356,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Innealta Capital LLC bought a new stake in shares of Hologic in the second quarter worth approximately $25,000. iA Global Asset Management Inc. bought a new position in shares of Hologic during the 1st quarter valued at $37,000. Cranbrook Wealth Management LLC bought a new position in shares of Hologic during the 2nd quarter valued at $47,000. Mather Group LLC. bought a new stake in shares of Hologic in the first quarter worth $48,000. Finally, Massmutual Trust Co. FSB ADV grew its holdings in shares of Hologic by 24.7% in the first quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock worth $54,000 after acquiring an additional 137 shares during the period. Institutional investors own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on HOLX shares. Royal Bank of Canada reissued a “sector perform” rating and issued a $82.00 target price on shares of Hologic in a research report on Friday, August 16th. Evercore ISI boosted their target price on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research report on Tuesday, July 30th. Stephens reiterated an “overweight” rating and issued a $92.00 price target on shares of Hologic in a research report on Tuesday, July 30th. JPMorgan Chase & Co. boosted their price objective on shares of Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a research report on Tuesday, July 30th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 target price on shares of Hologic in a report on Tuesday. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $87.60.

Hologic Price Performance

Shares of Hologic stock opened at $81.39 on Friday. The company has a market capitalization of $18.99 billion, a price-to-earnings ratio of 41.53, a PEG ratio of 2.53 and a beta of 0.98. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The stock’s 50-day simple moving average is $80.82 and its 200-day simple moving average is $77.10. Hologic, Inc. has a 52 week low of $64.02 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. During the same period in the previous year, the firm earned $0.93 EPS. The firm’s revenue was up 2.7% compared to the same quarter last year. As a group, analysts expect that Hologic, Inc. will post 4.09 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Hologic news, Director Christiana Stamoulis sold 9,039 shares of the business’s stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total value of $718,600.50. Following the sale, the director now owns 45,472 shares in the company, valued at approximately $3,615,024. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, Director Christiana Stamoulis sold 9,039 shares of Hologic stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total value of $718,600.50. Following the sale, the director now directly owns 45,472 shares of the company’s stock, valued at $3,615,024. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Benjamin Jordan Cohn sold 5,093 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $81.99, for a total value of $417,575.07. Following the transaction, the insider now directly owns 10,476 shares of the company’s stock, valued at $858,927.24. The disclosure for this sale can be found here. Over the last quarter, insiders sold 18,280 shares of company stock worth $1,469,973. 1.75% of the stock is owned by insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.